Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2009

DNDi to Search Pfizer’s Chemical Library for Potential HAT, VL, and Chagas Disease Treatments

  • The Drugs for Neglected Diseases initiative (DNDi) has gained access to the Pfizer library of novel chemical entities. DNDi will screen the compounds for their potential to be developed into new treatments for human African trypanosomiasis (HAT), visceral leishmaniasis (VL), and Chagas disease.

    Under the agreement, scientists in institutes affiliated with DNDi will test at least 150,000 compounds in the Pfizer library against Trypanosoma brucei, Leishmania donovani, and Trypanosoma cruzi, the parasites that cause HAT, VL, and Chagas disease, respectively. Researchers will seek compounds that show initial activity against the various parasites.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »